Back

Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation - Stroke prevention 1 Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mr Amol Dhamane

Bristol-Myers Squibb, Lawrenceville (United States of America)

9 More presentations in this session

Presentation thumbnail
Different obesity paradox of ischemic stroke without and with atrial fibrillation
Associate Professor Y. Baek (Incheon, KR)
Abstract
Presentation thumbnail
Anticoagulation control in octogenarian patients receiving vitamin K antagonists for stroke prevention in atrial fibrillation: the west birmingham AF project
Doctor H. Zulkifly (Selangor, MY)
Abstract Slides
Presentation thumbnail
Temporal trends in antithrombotic patterns for stroke prevention in patients with atrial fibrillation and wide spectrum of coronary artery disease
Associate Professor B. Hudzik (Zabrze, PL)
Abstract Slides
Presentation thumbnail
Dabigatran in real-world asian patients with atrial fibrillation with low body weight: nationwide cohort data covering the entire korean population
Doctor D. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Secondary stroke prophylaxis in atrial fibrillations patients with chronic kidney disease: a nationwide cohort study
Mr M. Christensen (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation - Stroke prevention 1

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources